Advertisement

Epidemiology of infectious complications in cancer patients

  • Teresa Zembower
Part of the Cancer Treatment and Research book series (CTAR)

Abstract

Infectious complications are a serious cause of morbidity and mortality in cancer patients, especially those with underlying hematologic malignancies. Several large studies have estimated that 70–75% of deaths in patients with acute leukemia are caused by infection, with or without hemorrhage [1, 2, 3]. Fewer data exist on infectious mortality in patients with solid organ tumors; however, approximately 50% of these patients are estimated to have an infection as either the primary or an associated cause of death [4,5]. Because patients with underlying malignancies are a heterogeneous group, an epidemiologic review of infections in these patients must take into account the diversity of the patient population. The nature of the underlying malignancy, the immunodeficiencies associated with it, and the treatments directed against it are all important determinants of infection.

Keywords

Central Venous Catheter Acute Leukemia Clin Infect Neutropenic Patient Hairy Cell Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chang H, Rodriguez V, Narboni G, et al. Causes of death in adults with acute leukemia. Medicine 1976;55:259–268.PubMedGoogle Scholar
  2. 2.
    Hughes WT. Fatal infections in childhood leukemia. Am J Dis Child 1971;122:283–287.PubMedGoogle Scholar
  3. 3.
    Hersh EM, Bodey GP, Nies BA, et al. Causes of death in acute leukemia. JAMA 1965;193:99–103.Google Scholar
  4. 4.
    Morrittu L, Earl HM, Souhami RL, et al. Patients at risk of chemotherapy-associated toxicity in small cell lung cancer. Br J Cancer 1989;59:801–804.Google Scholar
  5. 5.
    Viscoli C, Castagnola E. Factors predisposing cancer patients to infection. In: Klastersky J, ed. Infectious Complications of Cancer. Boston: Kluwer Academic, 1995, pp. 1–30.Google Scholar
  6. 6.
    Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966:64:328–340.PubMedGoogle Scholar
  7. 7.
    Feld R, Bodey GP. Infections in patients with malignant lymphoma treated with combination chemotherapy. Cancer 1977;39:1018–1025.PubMedGoogle Scholar
  8. 8.
    Glauser MP, Zinner SH. Mechanisms of acquisition and development of bacterial infections in cancer patients. In: Klastersky J, ed. Infections in Cancer Patients. New York: Raven Press, 1982, pp. 13–30.Google Scholar
  9. 9.
    De Jongh CS, Joshi JH, Newman KA, et al. Antibiotic synergism and response in gram-negative bacteremia in granulocytopenic cancer patients. Am J Med 1986;80:96–100.Google Scholar
  10. 10.
    Wade JC, Schimpff SC. Epidemiology and prevention of infection in the compromised host. In: Rubin RH, Young LS, eds. Clinical Approach to Infection in the Compromised Host. New York: Plenum Medical, 1988, pp. 5–40.Google Scholar
  11. 11.
    Dale DC, Guerry DI, Wewerka JR, et al. Chronic neutropenia. Medicine 1979:58:128–144.PubMedGoogle Scholar
  12. 12.
    Viscoli C, Bruzzi P, Castagnola E, et al. Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. Eur J Cancer 1994;30A:430–437.PubMedGoogle Scholar
  13. 13.
    The EORTC International Antimicrobial Therapy Project Group. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J Infect Dis 1978;137:14–29.Google Scholar
  14. 14.
    Schimpff SC, Young VM, Greene WH, et al. Origin of infection in acute nonlymphocytic leukemia: Significance of hospital acquisition of potential pathogens. Ann Intern Med 1972;77:707–714.PubMedGoogle Scholar
  15. 15.
    The EORTC International Antimicrobial Therapy Project Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987:317:1692–1698.Google Scholar
  16. 16.
    Johanson WG, Pierce AK, Sanford JP. Changing pharyngeal bacterial flora of hospitalized patients. Emergence of gram-negative bacilli. N Engl J Med 1969;281:1137–1140.PubMedGoogle Scholar
  17. 17.
    Cometta A, Calandra T, Bille J, et al. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 1994;330:1240–1241.PubMedGoogle Scholar
  18. 18.
    Levine SS, Schimpff SC, Graw RG Jr., et al. Hematologic malignancies and other marrow failure states: Progress in the management of complicating infections. Semin Hematol 1974;11:141–202.PubMedGoogle Scholar
  19. 19.
    Chanock S. Evolving risk factors for infectious complications of cancer therapy. Hematol Oncol Clin North Am 1993;7:771–793.PubMedGoogle Scholar
  20. 20.
    Koll BS, Brown AE. Changing patterns of infection in the immunocompromised patient with cancer. Hematol Oncol Clin North Am 1993;7:753–769.PubMedGoogle Scholar
  21. 21.
    Guiot HFL, Fibbe WE, van’t Wout JW. Risk factors for fungal infection in patients with malignant hematologic disorders: Implications for empirical therapy and prophylaxis. Clin Infect Dis 1993:18:525–532.Google Scholar
  22. 22.
    Warren JR, Scarpelli DG, Reddy JK, et al. Chronic inflammation and repair. In: Essentials of General Pathology. New York: Macmillan, 1987, pp. 27–46.Google Scholar
  23. 23.
    Johnston RB, Jr. Monocytes and macrophages. N Engl J Med 1988;318:747–752.PubMedGoogle Scholar
  24. 24.
    Young RC, Corder MP, Haynes HA, et al. Delayed hypersensitivity in Hodgkin’s disease. A study of 103 untreated patients. Am J Med 1972;52:63–72.PubMedGoogle Scholar
  25. 25.
    Seligmann M, Chess L, Fahey JL, et al. AIDS —An immunologic reevaluation. N Engl J Med 1984;311:1286–1292.PubMedGoogle Scholar
  26. 26.
    Aubertin J, Lacut JY, Hoerni B, et al. Factors favoring infections in cancer patients. In: Armstrong D, ed. Opportunistic Infections in Cancer Patients. New York: Masson, 1978, pp. 16–28.Google Scholar
  27. 27.
    Krick J, Remington J. Opportunistic fungal infection in patients with leukemia and lymphoma. Clin Hematol 1976;5:249–310.Google Scholar
  28. 28.
    Lum LG. Immune recovery after bone marrow transplantation. Bone Marrow Transplant Hematol Oncol Clin North Am 1990;4:659–675.Google Scholar
  29. 29.
    Whittaker K, Rees K, Clark CG. Reduced lymphocyte transformation in breast cancer. Lancet 1971;l:892–893.Google Scholar
  30. 30.
    Han T, Takita H. Immunologic impairment in bronchogenic carcinoma: A study of lymphocyte response to phytohemagglutinin. Cancer 1972;30:616–620.PubMedGoogle Scholar
  31. 31.
    Brooks WH, Netsky MG, Normansell DE, et al. Depressed cell-mediated immunity in patients with primary intracranial tumors. J Exp Med 1972;136:1631–1647.PubMedGoogle Scholar
  32. 32.
    Orita K, Miwa H, Fukada H, et al. Preoperative cell-mediated immune status of gastric cancer patients. Cancer 1976;38:2343–2348.PubMedGoogle Scholar
  33. 33.
    Schellhammer PF, Bracken RB, Bean MA, et al. Immune evaluation with skin testing. A study of testicular, prostate and bladder neoplasms. Cancer 1976;38:149–156.PubMedGoogle Scholar
  34. 34.
    Mackall CL, Fleisher TA, Brown MR, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994;84:2221–2228.PubMedGoogle Scholar
  35. 35.
    Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995;332:143–149.PubMedGoogle Scholar
  36. 36.
    Kim JH, Perfect JR. Infection and cyclosporine. Rev Infect Dis 1989;11:677–690.PubMedGoogle Scholar
  37. 37.
    Bishop JF, Schimpff SC, Diggs CH, et al. Infections during intensive chemotherapy for non-Hodgkin’s lymphoma. Ann Intern Med 1981;95:549–555.PubMedGoogle Scholar
  38. 38.
    Bookman MA, Longo DL. Concomitant illness in patients treated for Hodgkin’s disease. Cancer Treat Rev 1986;13:77–111.PubMedGoogle Scholar
  39. 39.
    Hardy I, Gershon AA, Steinberg SP, et al. The incidence of zoster after immunization with live attenuated varicella vaccine. N Engl J Med 1991;325:1545–1550.PubMedGoogle Scholar
  40. 40.
    Hughes WT, Townsend TR. Nosocomial infections in immunocompromised children. Am J Med 1981;70:412–416.PubMedGoogle Scholar
  41. 41.
    Ampel NM, Wing EJ. Legionellosis in the compromised host. In: Rubin RH, Young LL, eds. Clinical Approach to Infection in the Compromised Host. New York: Plenum Medical, 1988, pp. 305–319.Google Scholar
  42. 42.
    Luft BJ, Remington JS. Toxoplasmosis of the central nervous system. Curr Clin Top Infect Dis 1985;6:315–358.Google Scholar
  43. 43.
    Longworth DL, Weller PF. Hyperinfection syndrome with strongyloidiasis. Curr Clin Top Infect Dis 1986;7:1–26.Google Scholar
  44. 44.
    Varthalitis I, Meunier F. Pneumocystis carinii pneumonia in cancer patients. Cancer Treat Rev 1993;19:387–413.PubMedGoogle Scholar
  45. 45.
    Sepkowitz KA, Brown AE, Telzak EE, et al. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992;267:832–837.PubMedGoogle Scholar
  46. 46.
    Sepkowitz KA. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis 1993;17(Suppl. 2):S416–S422.PubMedGoogle Scholar
  47. 47.
    Hughes WT, Feldman S, Aur RJA, et al. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer 1975;36:2004–2009.PubMedGoogle Scholar
  48. 48.
    Salmon SE. Immunoglobulin synthesis and tumor kinetics of multiple myeloma. Semin Hematol 1973;10:135–147.PubMedGoogle Scholar
  49. 49.
    Fahey JL, Scoggins R, Utz JP, et al. Infection, antibody response and gamma globulin components in multiple myeloma and macroglobulinemia. Am J Med 1963;35: 698–707.PubMedGoogle Scholar
  50. 50.
    Jacobson DR, Zolla-Pazner S. Immunosuppression and infection in multiple myeloma. Semin Oncol 1986;13:282–290.PubMedGoogle Scholar
  51. 51.
    Mordasini RC, Keller H, Schlumpf E, et al. Humorale Infektabwherschwache bei paraproteinamischen Erkrankungen. Schewiz Med Wschr 1972;102:625–635.PubMedGoogle Scholar
  52. 52.
    Homberg JC, Cartron J, Ropars C, et al. Anomalies immunologiques observees au cours des leucemies lymphoides chroniques hyperlymphocytaires. Nouv Rev Fr Hematol 1971;11:476–483.PubMedGoogle Scholar
  53. 53.
    Sheridan JF, Tutschka PJ, Sedmak DD, et al. Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation. Blood 1990;75:1583–1586.PubMedGoogle Scholar
  54. 54.
    Atkinson K. Reconstruction of the haemopoietic and immune systems after bone marrow transplantation. Bone Marrow Transpl 1990;5:209–226.Google Scholar
  55. 55.
    Axelrod PI, Lorber B, Vonderheid EC. Infections complicating mycosis fungoides and Sezary syndrome. JAMA 1992;267:1354–1358.PubMedGoogle Scholar
  56. 56.
    Awada A, van der Auwera P, Meunier F, et al. Streptococcal and enterococcal bacteremia in patients with cancer. Clin Infect Dis 1992;15:33–48.PubMedGoogle Scholar
  57. 57.
    Hosea SW, Brown EJ, Hamburger MI, et al. Opsonic requirements for intravascular clearance after splenectomy. N Engl J Med 1981;304:245–250.PubMedGoogle Scholar
  58. 58.
    Van Der Meer JWM. Defects in host-defense mechanisms. In: Rubin RH, Young LS, eds. Clinical Approach to Infection in the Compromised Host. New York: Plenum Medical, 1988, pp. 41–63.Google Scholar
  59. 59.
    Gopal V, Bison AL. Fulminant pneumococcal infections in “normal” asplenic hosts. Arch Intern Med 1977;137:1526–1530.PubMedGoogle Scholar
  60. 60.
    Advisory Committee on Immunization Practices. Pneumococcal polysaccharide vaccine. MMWR 1989;38:64–68, 73-76.Google Scholar
  61. 61.
    Kahls P, Kier P, Lechner K. Functional asplenia after bone marrow transplantation. Ann Intern Med 1990; 114:805–806.Google Scholar
  62. 62.
    Schimpff SC. Infections in the cancer patient — Diagnosis, prevention, and treatment. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practices of Infectious Diseases. New York: Churchill Livingstone, 1995, pp. 2666–2675.Google Scholar
  63. 63.
    Schwartz SN, Dowling JN, Benkovic C, et al. Sources of gram-negative bacilli colonizing the trachea of intubated patients. J Infect Dis 1978:138:227–231.PubMedGoogle Scholar
  64. 64.
    Kelly CP, Pothoulakis C, Lamont JT. Clostridium difficle colitis. N Engl J Med 1994;330:257–262.PubMedGoogle Scholar
  65. 65.
    Anand A, Glatt A. Clostridium difficle infection associated with antineoplastic chemotherapy: A review. Clin Infect Dis 1993;17:109–113.PubMedGoogle Scholar
  66. 66.
    Fan-Havard P, Capano D, Smith SM, et al. Development of resistence in Candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother 1978;35:2302–2305.Google Scholar
  67. 67.
    Meunier F, Aoun M, Bitar N. Candidemia in immunocompromised patients. Clin Infect Dis 1992;14(Suppl. l):S120–S125.PubMedGoogle Scholar
  68. 68.
    Boken DJ, Swindells S, Rinaldi MG. Fluconazole-resistant Candida albicans. Clin Infect Dis 1993;17:1018–1021.PubMedGoogle Scholar
  69. 69.
    Aisner J, Schmipff SC, Sutherland JC, et al. Torulopsis glabrata infections in patients with cancer. Am J Med 1976;61:23–28.PubMedGoogle Scholar
  70. 70.
    Merz WG, Karp JE, Schron D, et al. Increased incidence of fungemia caused by Candida krusei. J Clin Microbiol 1986;24:581–584.PubMedGoogle Scholar
  71. 71.
    Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;325:1274–1277.PubMedGoogle Scholar
  72. 72.
    van der Waaij DD, Berghuis J, Lekkerkerk JEC. Colonization resistance of the digestive tract of mice during systemic antibiotic treatment. J Hyg (Camb) 1972;70:605–610.Google Scholar
  73. 73.
    Wilson BD, Surgalla MJ, Yates JW. Aerobic and anaerobic surgical wound contamination in patients with cancer. Surg Gynecol Obstet 1974;139:329–332.PubMedGoogle Scholar
  74. 74.
    Rolandelli R, Roslyn JJ. The colon and rectum. Surgical anatomy and operative procedures. In: Sabiston DCJ, Lyerly HK, eds. Textbook of Surgery. The Biological Basis of Modern Surgical Practice. Philadelphia: W.B. Saunders, 1997, pp. 971–975.Google Scholar
  75. 75.
    Gongaware RD, Slanetz CAJ. Hartmann procedure for carcinoma of the sigmoid and rectum. Ann Surg 1973;178:28–30.PubMedGoogle Scholar
  76. 76.
    Naito H, Toya S, Shizawa H, et al. High incidence of acute post operative meningitis and septicemia in patients undergoing craniotomy with vertriculoatrial shunt. Surg Gynecol Obstet 1973:137:810–812.PubMedGoogle Scholar
  77. 77.
    Geelhoed GW, Ketcham AS. Pseudomonas meningitis complicating radical resection for radiorecurrent cancer of paranasal sinuses: Report of two patients successfully treated with intrathecal polymyxin. J Surg Oncol 1973;5:365–374.PubMedGoogle Scholar
  78. 78.
    Harris M, Gumport S, Berman I, et al. Ilioinguinal lymph node dissecton for melanoma. Surg Gynecol Obstet 1973;136:33–39.PubMedGoogle Scholar
  79. 79.
    Villar HV, Warneke JA, Peck MD, et al. Role of surgical treatment in the management of complications of the gastrointestinal tract in patients with leukemia. Surg Gynecol Obstet 1987;165:217–222.PubMedGoogle Scholar
  80. 80.
    Wade DS, Nava HR, Douglass HOJ. Neutropenic enterocolitis. Clinical diagnosis and treatment. Cancer 1992;69:17–23.PubMedGoogle Scholar
  81. 81.
    Schimpff SC, O’Connel MJ, Greene WH, et al. Infections in 92 splenectomized patients with Hodgkin’s disease. Am J Med 1975;59:695–701.PubMedGoogle Scholar
  82. 82.
    Say CC, Donegan W. A biostatistical evaluation of complications from mastectomy. Surg Gynecol Obstet 1974;138:370–376.PubMedGoogle Scholar
  83. 83.
    Smith MGM, Golding PL, Eddieston ALWF, et al. Cell-mediated immune responses in chronic liver diseases. Br Med J 1972;l:527–530.Google Scholar
  84. 84.
    Castagnola E, Garaventa A, Conte M, et al. Survival after fungemia due to Fusarium moniliforme in a child with neuroblastoma [letter]. Eur J Clin Microbiol Infect Dis 1993; 12:308–309.PubMedGoogle Scholar
  85. 85.
    Wade JC, Schimpff SC, Hargadon MT, et al. A comparison of trimethoprim-sulfamethoxazole plus nystatin with gentamicin plus nystatin in the prevention of infections in acute leukemia. N Engl J Med 1981;304:1057–1062.PubMedGoogle Scholar
  86. 86.
    Schimpff SC, Greene WH, Young WM, et al. Infection prevention in acute nonlymphocytic leukemia. Ann Intern Med 1975:82:351–358.PubMedGoogle Scholar
  87. 87.
    Hathorn JW. Critical appraisal of antimicrobials for prevention of infections in immunocompromised hosts. Hematol Oncol Clin North Am 1993;7:1051–1099.PubMedGoogle Scholar
  88. 88.
    McQuillen DP, Zingman BS, Meunier F, et al. Invasive infections due to Candida krusei: Report of ten cases of fungemia that include three cases of endophthalmitis. Clin Infect Dis 1992:14:472–478.PubMedGoogle Scholar
  89. 89.
    Shlaes DM, Binezewski B, Rice BL. Emerging antimicrobial resistance and the immunocompromised host. Clin Infect Dis 1993;17(Suppl. 2):S527–536.PubMedGoogle Scholar
  90. 90.
    Stosor V, Noskin GA, Peterson LR. The management and prevention of vancomycin-resistant enterococci. Infect Med 1996;13:488, 493–498.Google Scholar
  91. 91.
    Livornese LL, Dias S, Samel C, et al. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med 1992;117:112–116.PubMedGoogle Scholar
  92. 92.
    Groeger JS, Lucas AB, Thaler HT, et al. Venous access devices in patients with cancer. Ann Intern Med 1993:119:1168–1174.PubMedGoogle Scholar
  93. 93.
    Tenney JH, Moody MR, Newman KA, et al. Adherent microorganisms on lumenal surfaces of long-term intravenous catheters. Arch Intern Med 1986;146:1949–1954.PubMedGoogle Scholar
  94. 94.
    Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993:328:1323–1332.PubMedGoogle Scholar
  95. 95.
    Clarke DE, Raffin TA. Infectious complications of indwelling long-term central venous catheters. Chest 1990;97:966–972.PubMedGoogle Scholar
  96. 96.
    Abi-Nader JA. Peripherally inserted central venous catheters in critical care patients. Heart Lung 1993;22:428–434.PubMedGoogle Scholar
  97. 97.
    Lam S, Scannell R, Roessler D, et al. Peripherally inserted central catheters in an acute-care hospital. Arch Intern Med 1994;154:1833–1837.PubMedGoogle Scholar
  98. 98.
    Loughran SC, Borzatta M. Peripherally inserted central catheters: A report of 2506 catheter days. J Parent Ent Nut 1995;19:133–136.Google Scholar
  99. 99.
    Gottesdiener KM. Transplanted infections: Donor-to-host transmission with the allograft. Ann Intern Med 1989;110:1001–1016.PubMedGoogle Scholar
  100. 100.
    Barbara JAJ, Contreras M. Infectious complications of blood transfusion: Bacteria and parasites. Br Med J 1990;300:386–389.Google Scholar
  101. 101.
    Soulier JP. Diseases tramsmissible by blood transfusion. Vox Sang 1984;47:1–6.PubMedGoogle Scholar
  102. 102.
    Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494–1500.PubMedGoogle Scholar
  103. 103.
    Sayers MH, Anderson KC, Goodnough LT, et al. Reducing the risk for transfusion-transmitted cytomegalovirus infection. Ann Intern Med 1992;116:55–62.PubMedGoogle Scholar
  104. 104.
    Mayer KH, Opal SM. Unusual nosocomial pathogens. Infect Dis Clin North Am 1989;3:883–899.PubMedGoogle Scholar
  105. 105.
    Wittner M, Rowin KS, Tanowitz HB, et al. Successful chemotherapy for transfusion babesiosis. Ann Intern Med 1982;96:601–604.PubMedGoogle Scholar
  106. 106.
    Tabor E, Garety RJ. Five cases of Pseudomonas sepsis transmitted by blood transfusions. Lancet 1984;l:1403.Google Scholar
  107. 107.
    Wright DC, Selss IF, Vinton KJ, et al. Fatal Yersinia enterocolitica sepsis after blood transfusion. Arch Pathol Lab Med 1985;109:1040–1042.PubMedGoogle Scholar
  108. 108.
    Yomtovian R, Lazarus LT, Goodnough NV, et al. A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets. Transfusion 1993;33:902–909.PubMedGoogle Scholar
  109. 109.
    Schimpff SC. Therapy of infection in patients with granulocytopenia. Med Clin North Am 1977;61:1101–1118.PubMedGoogle Scholar
  110. 110.
    Bodey GP, Rodriguez V, Chang H, et al. Fever and infection in leukemic patients. A study of 494 consecutive patients. Cancer 1978;41:1610–1622.PubMedGoogle Scholar
  111. 111.
    Sanders JW, Powe NR, Moore RD. Ceftazidime monotherapy for empiric treatment of febrile neutroenic patients: A metaanalysis. J Infect Dis 1991;164:907–916.PubMedGoogle Scholar
  112. 112.
    Sanders CC. New B-lactams: New problems for the internist. Ann Intern Med 1991;115:650–651.PubMedGoogle Scholar
  113. 113.
    Whimbey E, Kiehn TE, Brannon P, et al. Bacteremia and fungemia in patients with neoplastic disease. Am J Med 1987;82:723–730.PubMedGoogle Scholar
  114. 114.
    Singer C, Kaplan MH, Armstrong D. Bacteremia and fungemia complicating neoplastic disease. Am J Med 1977;62:731–742.PubMedGoogle Scholar
  115. 115.
    The EORTC International Antimicrobial Therapy Cooperative Group. Gram-positive bacteremia in granulocytopenic cancer patients. Eur J Cancer 1990;26:569–574.Google Scholar
  116. 116.
    Viscoli C, Van der Auwera P, Meunier F. Gram-positive infections in granulocytopenic patients: An important issue? J Antimicrob Chemother 1988;21(Suppl. C):149–156.PubMedGoogle Scholar
  117. 117.
    Winston DJ, Dudnick DV, Chapin M, et al. Coagulase-negative staphylococcal bacteremia in patients receiving immunosuppressive therapy. Arch Intern Med 1983:143: 32–36.PubMedGoogle Scholar
  118. 118.
    Karp JE, Dick J, Angelopulos C, et al. Empiric use of vancomycin during prolonged treatment-induced granulocytopenia: Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. Am J Med 1986;81:237–242.PubMedGoogle Scholar
  119. 119.
    Arning M, Gehrt A, Aul C, et al. Septicemia due to Streptococcus mitis in neutropenic patients with acute leukemia. Blut 1990;61:364–368.PubMedGoogle Scholar
  120. 120.
    Neu HC. The crisis in antibiotic resistance. Science 1992;257:1064–1073.PubMedGoogle Scholar
  121. 121.
    Anaissie E. Opportunistic mycoses in the immunocompromised host: Experience at a cancer center and review. Clin Infect Dis 1992;14(Suppl. 1):S43–53.PubMedGoogle Scholar
  122. 122.
    Meunier-Carpentier F, Kiehn TE, Armstrong D. Fungemia in the immunocompromised host: Changing patterns, antigenemia, high mortality. Am J Med 1981;71:363–370.PubMedGoogle Scholar
  123. 123.
    Lecciones JA, Lee JW, Navarro EE, et al. Vascular catheter-associated fungemia in patients with cancer: Analysis of 155 episodes. Clin Infect Dis 1992;14:875–883.PubMedGoogle Scholar
  124. 124.
    Wey SB, Mori M, Pfaller MA, et al. Hospital-acquired candidemia: The attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642–2645.PubMedGoogle Scholar
  125. 125.
    Gerson SL, Talbot GH, Hurwitz S, et al. Prolonged granulocytopenia: The major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984;100:345–351.PubMedGoogle Scholar
  126. 126.
    Fischer BD, Armstrong D, Yu B, et al. Invasive aspergillosis: Progress in early diagnosis and treatment. Am J Med 1981;71:571–577.Google Scholar
  127. 127.
    De Gregorio M, Lee W, Linker C, et al. Fungal infections in patients with acute leukemia. Am J Med 1982;73:543–548.Google Scholar
  128. 128.
    Hawkins C, Armstrong D. Fungal infections in the immunocompromised host. Clin Haematol 1984;3:599–630.Google Scholar
  129. 129.
    Bodey G, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: An international autopsy survey. Eur J Microbiol Infect Dis 1992;11:99–109.Google Scholar
  130. 130.
    Corey L, Spear PG. Infections with Herpes simplex virus. N Engl J Med 1986;314:686–691, 749-757.PubMedGoogle Scholar
  131. 131.
    Rand KH, Kramer B, Johnson AC. Cancer chemotherapy associated symptomatic stomatitis: Role of Herpes simplex virus (HSV). Cancer 1982;50:1262–1265.PubMedGoogle Scholar
  132. 132.
    Buss DH, Scharyj M. Herpesvirus infection of the esophagus and other visceral organs in adults: Incidence and clinical significance. Am J Med 1979;66:457–462.PubMedGoogle Scholar
  133. 133.
    Ramsey PG, Fife KH, Hackman RC, et al. Herpes simplex virus pneumonia: Clinical, virologic, and pathologic features in 20 patients. Ann Intern Med 1982;97:813–820.PubMedGoogle Scholar
  134. 134.
    Straus SE, Ostrove JM, Inchauspe G, et al. Varicella-zoster virus infections: Biology, natural history, treatment, and prevention. Ann Intern Med 1988;108:221–237.PubMedGoogle Scholar
  135. 135.
    Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986;153:478–488.PubMedGoogle Scholar
  136. 136.
    Kaplan LJ, Daum RS, Smaron M, et al. Severe measles in immunocompromised patients. JAMA 1992;267:1237–1241.PubMedGoogle Scholar
  137. 137.
    Zahradnik JM, Spencer MJ, Porter DD. Adenovirus infection in the immunocompromised patient. Am J Med 1980;68:725–732.PubMedGoogle Scholar
  138. 138.
    Meunier F. Infections in patients with acute leukemia and lymphoma. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practices of Infectious Diseases. New York: Churchill Livingstone, 1995, pp. 2675–2686.Google Scholar
  139. 139.
    Cotran RS, Kumar V, Robbins SL. Diseases of white cells, lymph nodes, and spleen. In: Robbins Pathologic Basis of Disease. Philadelphia: W.B. Saunders, 1989, pp. 703–754.Google Scholar
  140. 140.
    Goyal R, Bajpai S, Chopra HK, et al. Hairy cell leukemia — an unusual presentation. Leuk Res 1995;19:485–487.PubMedGoogle Scholar
  141. 141.
    Mackowiak PA, Demian SE, Sutker WL, et al. Infections in hairy cell leukemia: Clinical evidence of a pronounced defect in cell-mediated immunity. Am J Med 1980;68:718–723.PubMedGoogle Scholar
  142. 142.
    Bennett C, Vardiman J, Golomb H. Disseminated atypical mycobacterial infection in patients with hairy cell leukemia. Am J Med 1966;80:891–896.Google Scholar
  143. 143.
    Attal M, Schlaifer D, Rubie H, et al. Prevention of gram-positive infections after bone marrow transplantation by systemic vancomycin: A prospective, randomized trial. J Clin Oncol 1991;9:865–870.PubMedGoogle Scholar
  144. 144.
    Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845–851.PubMedGoogle Scholar
  145. 145.
    Goodrich JM, Reed EC, Mori M, et al. Clinical features and analysis of risk factors for invasive candidat infection after marrow transplantation. J Infect Dis 1991;164:731–740.PubMedGoogle Scholar
  146. 146.
    Derouin F, Devergie A, Auber P, et al. Toxoplasmosis in bone marrow-transplant recipients: Report of seven cases and review. Clin Infect Dis 1992;15:267–270.PubMedGoogle Scholar
  147. 147.
    Miller W, Flynn P, McCulough J, et al. Cytomegalovirus infection after bone marrow transplantation: An association with acute graft-v-host disease. Blood 1986;67:1162–1167.PubMedGoogle Scholar
  148. 148.
    Wingard JR, Mellits D, Sostrin MB, et al. Interstitial penumonitis after allogeneic bone marrow transplantation: Nine year experience at a single institution. Medicine 1988;67:175–186.PubMedGoogle Scholar
  149. 149.
    Pannuti CS, Gingrich RD, Pfaller MA, et al. Nosocomial pneumonia in adult patients undergoing bone marrow transplantation: A 9 year study. J Clin Oncol 1991;9:77–84.PubMedGoogle Scholar
  150. 150.
    Meyers JD, Thomas ED. Infection complicating bone marrow transplantation. In: Rubin RH, Young LS, eds. Clinical Approach to Infection in the Compromised Host. New York: Plenum Medical, 1988, pp. 525–556.Google Scholar
  151. 151.
    Hiemenz JW, Greene JN. Special considerations for the patient undergoing allogeneic or autologous bone marrow transplantation. Hematol Oncol Clin North Am 1993;7:961–1002.PubMedGoogle Scholar
  152. 152.
    Rubin RH, Ferraro MJ. Understanding and diagnosing infectious complications in the immunocompromised host. Hematol Oncol Clin North Am 1993;7:795–812.PubMedGoogle Scholar
  153. 153.
    Cohen ML. Epidemiology of drug resistance: Implications for a post-antimicrobial era. Science 1992;257:1050–1055.PubMedGoogle Scholar
  154. 154.
    Kunin CM. Resistance to antimicrobial drugs —A worldwide calamity. Ann Intern Med 1993;118:557–561.PubMedGoogle Scholar
  155. 155.
    Leclercq R, Derlot E, Duval J, et al. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988;319:157–161.PubMedGoogle Scholar
  156. 156.
    Montecalvo MA, Horowitz H, Gedris C, et al. Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother 1994;38:1363–1367.PubMedGoogle Scholar
  157. 157.
    Noskin GA, Cooper I, Peterson L. Vancomycin-resistant Enterococcus faecium sepsis following persistent colonization. Arch Intern Med 1995;155:1445–1447.PubMedGoogle Scholar
  158. 158.
    Infectious Diseases Society of America. IDSA disseminates the latest on infectious diseases. Infect Dis Alert 1996;16:38–39.Google Scholar
  159. 159.
    Bouchud PY, Calandra T, Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: A review. Am J Med 1994;97:256–264.Google Scholar
  160. 160.
    Kern W, Kurrle E, Schmeiser T. Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. A review of 55 cases. Infection 1990;18:138–145.PubMedGoogle Scholar
  161. 161.
    Elting LS, Bodey GP, Keefe BH. Septicimia and shock syndrome due to viridans streptococci: A case-control study of predispoisng factors. Clin Infect Dis 1992;14:1201–1207.PubMedGoogle Scholar
  162. 162.
    Borek AP, Dressel DC, Hussong J, et al. Changing susceptibility of Streptococcus pneumoniae to antimicrobial agents in Chicago, Illinois between 1993 and 1996: The need for accurate laboratory identification and susceptibility testing. Diagn Microbiol Infect Dis 1997;29:209–214.PubMedGoogle Scholar
  163. 163.
    Handwerger S, Horowitz H, Coburn K, et al. Infection due to Leuconostoc species: Six cases and review. Rev Infect Dis 1990;12:602–610.PubMedGoogle Scholar
  164. 164.
    Ascher DP, Zbick C, White C, et al. Infections due to Stomatococcus mucilaginosus: 10 cases and review. Rev Infect Dis 1991;13:1048–1052.PubMedGoogle Scholar
  165. 165.
    McWhinney PH, Kibbler CC, Gillespie SH, et al. Stomatococcus mucilaginosus: An emerging pathogen in neutropenic patients. Clin Infect Dis 1992;14:641–646.PubMedGoogle Scholar
  166. 166.
    Young VM, Meyers WF, Moody MR, et al. The emergence of coryneform bacteria as a cause of nosocomial infections in compromised hosts. Am J Med 1981;70:646–650.PubMedGoogle Scholar
  167. 167.
    Riebel W, Frantz N, Adelstein D, et al. Corynebacterium JK: A cause of nosocomial device-related infection. Rev Infect Dis 1986;8:42–49.PubMedGoogle Scholar
  168. 168.
    Johnson A, Hulse P, Oppenheim BA. Corynebacterium jeikeium meningitis and transverse meylitis in a neutropenic patient. Eur J Clin Microbiol Infect Dis 1992;11:473–474.PubMedGoogle Scholar
  169. 169.
    Henrickson K, Shenep J, Flynn P, et al. Primary cutaneous Bacillus cereus infection in neutropenic children. Lancet 1989;l:601–603.Google Scholar
  170. 170.
    Tuazon CU. Other Bacillus species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. New York: Churchill Livingstone, 1995, pp. 1890–1894.Google Scholar
  171. 171.
    Harvey RL, Sunstrum JC. Rhodococcus equi infection in patients with and without human immunodeficiency virus infection. Rev Infect Dis 1991;13:139–145.PubMedGoogle Scholar
  172. 172.
    Khardori N, Elting L, Wong E, et al. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis 1990;12:997–1003.PubMedGoogle Scholar
  173. 173.
    Garau J. Beta-lactamases: Current situation and clinical importance. Intensive Care Med 1994;20:S5–S9.PubMedGoogle Scholar
  174. 174.
    Sirot D. Extended-spectrum plasmid-mediated B-lactamases. J Antimicrob Chemother 1995;36(Suppl. A):19–34.PubMedGoogle Scholar
  175. 175.
    Meyer KS, Urban C, Eagan JA, et al. Nosocomial outbreak of Klebsiella infection resistant to late-genertation cephalosporins. Ann Intern Med 1993; 119:353–358.PubMedGoogle Scholar
  176. 176.
    Pegues DA, Carson LA, Anderson RL, et al. Outbreak of Pseudomonas cepacia bacteremia in oncology patients. Clin Infect Dis 1993;16:407–411.PubMedGoogle Scholar
  177. 177.
    Kaye KM, Macone A, Kazanjian PH. Catheter infection caused by Methylobacterium in immunocompromised hosts: Report of three cases and review of the literature. Clin Infect Dis 1992:14:1010–1014.PubMedGoogle Scholar
  178. 178.
    Edmond MB, Riddler SA, Baxter CM, et al. Agrobacterium radiobacter. A recently recognized opportunistic pathogen. Clin Infect Dis 1993;16:388–391.PubMedGoogle Scholar
  179. 179.
    Cieslak TJ, Robb ML, Drabick CJ, et al. Catheter-associated sepsis caused by Ochrobactrum anthropi: Report of a case and review of related nonfermentative bacteria. Clin Infect Dis 1992;14:902–907.PubMedGoogle Scholar
  180. 180.
    Legrand C, Anaissie E. Bacteremia due to Achromobacter xylosoxidans in patients with cancer. Clin Infect Dis 1992;14:479–484.PubMedGoogle Scholar
  181. 181.
    Kim JH, Cooper RA, Welty-Wolf KE, et al. Pseudomonas putrefaciens bacteremia. Rev Infect Dis 1989;ll:97–104.Google Scholar
  182. 182.
    Bilgrami S, Bergstrom SK, Peterson DE, et al. Capnocytophaga bacteremia in a patient with Hodgkin’s disease following bone marrow transplantation: Case report and review. Clin Infect Dis 1992:14:1045–1049.PubMedGoogle Scholar
  183. 183.
    Lorber B. Gas gangrene and other Clostridium-associated diseases. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. New York: Churchill Livingstone, 1995, pp. 2182–2195.Google Scholar
  184. 184.
    Valtonen M, Sivonen A, Elonen E. A cluster of seven cases of Clostridium tertium septicemia in neutropenic patients. Eur J Clin Microbiol Infect Dis 1990;9:40–42.PubMedGoogle Scholar
  185. 185.
    Zinner SH. New and unusual infections in neutropenic patients. In: Klastersky J, ed. Infectious Complications of Cancer. Boston: Kluwer Academic, 1995, pp. 173–184.Google Scholar
  186. 186.
    Huyghebaert MF, Dreyfus F, Paul G, et al. Septicemie a Fusobacterium nuleatum, producteur de beta-lactamase chez un sujet neutropenique. Ann Med Interne (Paris) 1989:140:225–226.Google Scholar
  187. 187.
    Weinberger M, Wu T, Rubin M, et al. Leptotricha buccalis bacteremia in patients with cancer: Report of four cases and review. Rev Infect Dis 1991;13:201–206.PubMedGoogle Scholar
  188. 188.
    Simon HB. Mycobacterial and nocardial infections in the compromised host. In: Rubin RH, Young LS, eds. Clinical Approach to Infection in the Compromised Host. New York: Plenum, 1988, pp. 221–251.Google Scholar
  189. 189.
    McWhinney PH, Yates M, Prentice HG, et al. Infection caused by Mycobacterium chelonae: A diagnostic and therapeutic problem in the neutropenic patient. Clin Infect Dis 1992:14:1208–1212.PubMedGoogle Scholar
  190. 190.
    Raad I.I., Vartivarian S, Khan A, et al. Catheter-related infections caused by the Mycobacterium fortuitum complex: 15 cases and review. Rev Infect Dis 1991;13:1120–1125.PubMedGoogle Scholar
  191. 191.
    Kristjansson M, Bieluch VM, Byeff PD. Mycobacterium haemophilum infection in immunocompromised patients: Case report and review of the literature. Rev Infect Dis 1991;13:906–910.PubMedGoogle Scholar
  192. 192.
    Chatis PA, Crumpacker CS. Resistance of Herpesviruses to antiviral drugs. Antimicrob Agents Chemother 1992;36:1589–1595.PubMedGoogle Scholar
  193. 193.
    Lalezari J, Stagg R, Kupperman B, et al. Intravenous cidofovir for peripheral Cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1997;126:257–263.PubMedGoogle Scholar
  194. 194.
    Studies of ocular complications of AIDS Research Group and the AIDS Clinical Trials Group. Parenteral cidofovir for Cytomegalovirus retinitis in patients with AIDS: The HPMPC peripheral Cytomegalovirus retinitis trial. Ann Intern Med 1997;126:264–274.Google Scholar
  195. 195.
    Foreman KE, Friborg J, Kong W, et al. Propatation of a human Herpesvirus from AIDS-associated Kaposi’s sarcoma. N Engl J Med 1997;336:163–171.PubMedGoogle Scholar
  196. 196.
    Strauchen JA, Hauser D, Burstein D, et al. Body cavity-based malignant lymphoma containing Kaposi sarcoma-associated Herpesvirus in an HIV-negative man with previous Kaposi sarcoma. Ann Intern Med 1996;125:822–825.PubMedGoogle Scholar
  197. 197.
    Pfaller M, Wenzel R. Impact of the changing epidemiology of fungal infections in the 1990’s. Eur J Clin Microbiol Infect Dis 1992;11:287–291.PubMedGoogle Scholar
  198. 198.
    Walsh TJ, Lee J, Lecciones J, et al. Empiric therapy with amphotericin B in febrile granulocytopenic patients. Rev Infect Dis 1991;13:496–503.PubMedGoogle Scholar
  199. 199.
    Wingard J, Merz W, Saral R. Candida tropicalis: A major pathogen in immunocompromised patients. Ann Intern Med 1979;91:539–543.PubMedGoogle Scholar
  200. 200.
    Anaissie E, Bodey G. Nosocomial fungal infections: Old problems and new challenges. Infect Dis Clin North Am 1989;3:867–882.PubMedGoogle Scholar
  201. 201.
    Garnis AS, Gudnason T, Giebink GS, et al. Disseminated infection with Fusarium in recipients of bone marow transplants. Rev Infect Dis 1991;13:1077–1088.Google Scholar
  202. 202.
    Nucci M, Spector N, Lucena S, et al. Three cases of infection with Fusarium species on neutropenic patients. Eur J Clin Microbiol Infect Dis 1992;ll:1160–1162.Google Scholar
  203. 203.
    Bennett J. Miscellaneous fungi, and prototheca. In: Mandell G, Bennett J, Dolin R, eds. Principles and Practices of Infectious Diseases. New York: Churchill Livingstone, 1995, pp. 2389–2393.Google Scholar
  204. 204.
    Nahass GT, Rosenberg SP, Leonardi CL, et al. Disseminated infection with Trichosporon beigelii. Arch Dermatol 1993;129:1020–1023.PubMedGoogle Scholar
  205. 205.
    Walsh TJ, Newman KR, Moody M, et al. Trichosporonosis in patients with neoplastic disease. Medicine 1986;65:268–279.PubMedGoogle Scholar
  206. 206.
    Kalter DCA, Tschen JA, Cernoch PL, et al. Genital white piedra: Epidemiology, microbiology and therapy. J Am Acad Dermatol 1986;14:982–993.PubMedGoogle Scholar
  207. 207.
    Martino P, Venditti M, Micozzi A, et al. Blastoschizomyces capitatus: An emerging cause of invasive fungal disease in leukemia patients. Rev Infect Dis 1990;12:570–582.PubMedGoogle Scholar
  208. 208.
    Danker W, Spector S, Fierer J. Malassezia fungemia in neonates and adults: Complication of hyperalimentation. Rev Infect Dis 1987;9:743–837.Google Scholar
  209. 209.
    Sudduth E, AJ CI, WE F. Phaeohyphomycosis due to Exophiala species: Clinical spectrum of disease in humans. Clin Infect Dis 1992;15:639–644.PubMedGoogle Scholar
  210. 210.
    Wood GM, McCormack JG, Muir DB, et al. Clinical features of human infection with Scedosporium inflatum. Clin Infect Dis 1992;14:1027–1033.PubMedGoogle Scholar
  211. 211.
    Wagner KF. Agents of chromomycosis. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. New York: Churchill Livingstone, 1995, pp. 2324–2327.Google Scholar
  212. 212.
    Anaissie E, Bodey GP, Kantarjian H, et al. New spectrum of fungal infections in patients with cancer. Rev Infect Dis 1989;ll:369–378.Google Scholar
  213. 213.
    Kiehn TE, Gorey E, Brown AE, et al. Sepsis due to Rhodotorula related to use of indwelling central venous catheters. Clin Infect Dis 1992;14:841–846.PubMedGoogle Scholar
  214. 214.
    Henson JW, Jalaj JK, Walker RW, et al. Pneumocystis carinii pneumonia in patients with primary brain tumors. Arch Neurol 1991;48:406–409.PubMedGoogle Scholar
  215. 215.
    Beaman MH, McCabe RE, Wong S, et al. Toxoplasma gondii. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. New York: Churchill Livingstone, 1995, pp. 2455–2475.Google Scholar
  216. 216.
    Ledingham JCG, Penfold WJ, Woodcock HM. Recent bacteriological experiences with typhoidal disease and dysentery: With notes on the protozoan parasites in the excreta. Br Med J 1915;2:704–711.Google Scholar
  217. 217.
    Faust EC, Giraldo LE, Caicedo G. Human isosporosis in the western hemisphere. Am J Trop Med Hyg 1961;10:343–349.PubMedGoogle Scholar
  218. 218.
    Gentile G, Venditti M, Micozzi A, et al. Cryptosporidiosis in patients with hematologic malignancies. Rev Infect Dis 1991;13:842–846.PubMedGoogle Scholar
  219. 219.
    Plumelle Y, Edouard A. Strongyloides stercoralis in T-cell leukemia/lymphoma in adults and acquired immunodeficiency syndrome. Rev Med Interne 1996;17:125–129.PubMedGoogle Scholar
  220. 220.
    Nucci M, Portugal R, Pulcheri W, et al. Strongyloidiasis in patients with hematologic malignancies. Clin Infect Dis 1995;21:675–677.PubMedGoogle Scholar
  221. 221.
    Savage D, Foadi M, Haworth C, et al. Marked eosinophilia in an immunosuppressed patient with strongyloidiasis. J Intern Med 1994;236:473–475.PubMedGoogle Scholar
  222. 222.
    Aydin H, Doppl W, Battmann A, et al. Opportunistic Strongyloides stercoralis hyper-infection in lymphoma patients undergoing chemotherapy and/or radiotherapy —report of a case and review of the literature. Acta Oncol 1994;33:78–80.PubMedGoogle Scholar
  223. 223.
    Simpson WG, Gerhardstein DC, Thompson JR. Disseminated Strongyloides stercoralis infection. South Med J 1993;86:821–825.PubMedGoogle Scholar
  224. 224.
    Wilkinson R, Leen CL. Chronic lymphocytic leukaemia and overt presentation of underlying Stronglyloides stercoralis infection. J Infection 1993;27:99–100.Google Scholar
  225. 225.
    Slater LN, Welch DF. Rochalimaea species (recently renamed Bartonella). In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. New York: Churchill Livingstone, 1995, pp. 1741–1747.Google Scholar
  226. 226.
    Heney C, Greeff M, Davis V. Hickman catheter-related Protothecal algaemia in an immunocompromised child. J Infect Dis 1991;163:930–931.PubMedGoogle Scholar
  227. 227.
    Kwon-Chung KJ, Bennett JE. Medical Mycology. Philadelphia: Lea & Febiger, 1992.Google Scholar
  228. 228.
    Kaminski ZC, Kapila R, Sharer LR, et al. Meningitis due to Prototheca wickerhamii in a patient with AIDS. Clin Infect Dis 1992;15:704–706.PubMedGoogle Scholar
  229. 229.
    Iacoviello VR, DeGirolami PC, Lucarini J, et al. Protothecosis complicating prolonged endotracheal intubation: Case report and literature review. Clin Infect Dis 1992;15:959–967.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1998

Authors and Affiliations

  • Teresa Zembower

There are no affiliations available

Personalised recommendations